Triple-Combination Acne Treatment Shows Promise in Clinical Studies

By the end of the 12-week trials, nearly half of the participants (around 50%) who used IDP-126 had achieved treatment success. This was a stark contrast to the control group, where only around a quarter of participants saw similar success. These results were statistically significant.

Furthermore, the IDP-126 group also showed a substantial reduction in both inflammatory and noninflammatory lesions compared to the control group. This indicates the potential of the triple-combination gel in effectively addressing various acne-related issues.

Notably, most of the treatment-emergent adverse events reported in both groups were of mild to moderate severity, suggesting that the IDP-126 gel is well-tolerated.

While these results are promising, it's essential to consider the limitations of the trials, including potential biases in assessing the severity of acne, the relatively short duration of treatment, and the specific demographics of the study participants.

Reference:

Stein Gold, L., Lain, E., Del Rosso, J. Q., Gold, M., Draelos, Z. D., Eichenfield, L. F., Sadick, N., Werschler, W. P., Gooderham, M. J., & Lupo, M. (2023). Clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel for moderate-to-severe acne: Efficacy and safety results from two randomized phase 3 trials. In Journal of the American Academy of Dermatology (Vol. 89, Issue 5, pp. 927–935). Elsevier BV. https://doi.org/10.1016/j.jaad.2022.08.069